HealthQuill Pharma
Zenas BioPharma, Inc. and China’s InnoCare Pharma Limited have inked a $2 billion licensing deal that grants the US-based Zenas global rights to develop and commercialise an investigational drug to treat multiple sclerosis (MS) and other autoimmune diseases.
Drugs Health Pharma

Zenas, InnoCare in $2b licensing deal for MS, autoimmune diseases

Zenas BioPharma, Inc. and China’s InnoCare Pharma Limited have inked a $2 billion licensing deal that grants the US-based Zenas global rights to.

Read More
US regulator rejects Fortress Biotech’s experimental pediatric medicine 
Drugs Medical Pharma

US regulator rejects Fortress Biotech’s experimental pediatric medicine 

The US regulator has declined to approve an experimental pediatric drug of Fortress Biotech Inc., an American biotechnology company, due to certain production.

Read More
Pfizer Inc., a US pharmaceutical company founded in 1849, has signed an agreement with the Trump administration to lower prices of prescription medicines in the North American nation
Drugs Medical Pharma

Pfizer inks deal with Trump to lower price of prescription drugs in US

Pfizer Inc., a US pharmaceutical company founded in 1849, has signed an agreement with the Trump administration to lower prices of prescription medicines.

Read More
Billionaire Bill Gates has pledged $912 million over three years, starting next year, to the Global Fund to Fight AIDS, Tuberculosis and Malaria.
Drugs Health Pharma

Bill Gates to spend $912 million to fight AIDS, tuberculosis, malaria

Billionaire Bill Gates has pledged $912 million over three years, starting next year, to the Global Fund to Fight AIDS, Tuberculosis and Malaria.

Read More
Pfizer Inc. will buy Matsera Inc. for $7.3 billion to eye at least four experimental drugs in the rapidly growing obesity market after it scrapped development of its own weight-loss pill in April this year.
Drugs Health Pharma

Pfizer to buy Matsera Inc. for $7.3 billion, eyes 4 anti-obesity drugs

Pfizer Inc. will buy Matsera Inc. for $7.3 billion to eye at least four experimental drugs in the rapidly growing obesity market after.

Read More
The US drug regulator, the Food and Drug Administration, has approved Merck & Co.’s new formulation of its cancer drug Keytruda that can be administered under the skin for adults.
Drugs Health Pharma

US approves Merck’s skin injectable version of cancer drug Keytruda

The US drug regulator, the Food and Drug Administration, has approved Merck & Co.’s new formulation of its cancer drug Keytruda that can.

Read More
Swiss healthcare multinational F. Hoffmann-La Roche AG will acquire US-based 89bio Inc. for a deal worth up to $3.5 billion to expand its metabolic disease portfolio.
Drugs Health Pharma

Roche to buy 89bio Inc for $3.5 billion to expand metabolic disease portfolio

Swiss healthcare multinational F. Hoffmann-La Roche AG will acquire US-based 89bio Inc. for a deal worth up to $3.5 billion to expand its.

Read More
https://www.novartis.com/research-and-development/research-disease-areas/cardiovascular-and-metabolic-disease-research-novartis
Drugs Health Pharma

Novartis signs $5.2 billion pact with China’s Argo Biopharmaceutical

HQ Team September 4, 2025: China’s Argo Biopharmaceutical Co., Ltd., and Switzerland’s Novartis AG have inked a $5.2 billion pact to develop new.

Read More
About 1.1 billion people globally are living with a mental disorder, mostly anxiety and depression disorders that together accounted for more than two-thirds of such conditions in 2021, according to two reports from the World Health Organization.
Health Pharma Research

‘In 2021, 1.1 billion people worldwide were living with mental disorders’

About 1.1 billion people globally are living with a mental disorder, mostly anxiety and depression disorders that together accounted for more than two-thirds.

Read More
Swedish-British AstraZeneca Plc’s medicine baxdrostat lowered blood pressure in trial patients during an end-stage study, and the company plans to file for regulatory approvals by the end of the year.
Drugs Health Pharma

AstraZeneca’s medicine lowers BP, to file for early approvals

Swedish-British AstraZeneca Plc’s medicine baxdrostat lowered blood pressure in trial patients during an end-stage study, and the company plans to file for regulatory.

Read More